We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Vivus, Inc., a pharmaceutical company dedicated to the development and commercialization of next-generation therapeutic products addressing obesity and sexual health, today announced that it has entered into a purchase agreement with two institutional investors for the sale of $12 million of its common stock in a registered direct offering.
Takeda Pharmaceutical plans to invest 200 billion yen (US$1.8 billion) in research and development for the year ending March 2007, up about 20%, becoming the first Japanese drug company to spend that much.
Data from a 10-year study showed that 92 percent of relapsing-remitting multiple sclerosis (RRMS) patients who remained on Teva's Copaxone (glatiramer acetate injection) were still walking without assistance despite an average disease duration of more than 15 years.
Velcade (bortezomib) for Injection has received Health Canada approval for the treatment of progressive multiple myeloma (a type of bone marrow cancer) in patients who have received at least one prior therapy and who have already undergone 2.
Valsartan, an angiotensin II antagonist, can have a positive effect on cardiac sympathetic nerve activity and left ventricular performance in patients with congestive heart failure (CHF), according to data published in the British journal Heart.
The Indian government's Department of Biotechnology has launched an initiative to develop a new human papilloma virus (HPV) vaccine, according to local reports.
Kos Pharmaceuticals, pharmaceutical company, reversed to a loss of 6 cents a share in Q1, hurt by inventory management agreements and stock option expenses despite 11% revenue growth.
Amarin Corporation plc today announced that it will be discussing its first quarter 2006 results in a conference call at 8.30 am Eastern Time/1.30 pm British Summer Time on Thursday, May 11th, 2006.